Holen Sie sich die Stockscreener-App
0.21
0.96%
0.002
Handel nachbörslich:
.21
Schlusskurs vom Vortag:
$0.208
Offen:
$0.209
24-Stunden-Volumen:
4.38M
Relative Volume:
0.82
Marktkapitalisierung:
$17.77M
Einnahmen:
$297.50K
Nettoeinkommen (Verlust:
$-72.19M
KGV:
-0.1226
EPS:
-1.7127
Netto-Cashflow:
$-54.39M
1W Leistung:
-37.54%
1M Leistung:
-51.53%
6M Leistung:
-78.35%
1J Leistung:
-83.72%
1-Tages-Spanne:
$0.1985
$0.232
1-Wochen-Bereich:
$0.1611
$0.37
52-Wochen-Spanne:
$0.1611
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Firmenname
Outlook Therapeutics Inc
Sektor
Branche
Telefon
(609) 619-3990
Adresse
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.21 | 17.60M | 297.50K | -72.19M | -54.39M | -1.7127 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-08-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-02 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-02-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-27 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-08-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-07-13 | Eingeleitet | CapitalOne | Overweight |
| 2023-04-03 | Eingeleitet | Guggenheim | Buy |
| 2023-02-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-31 | Eingeleitet | BTIG Research | Buy |
| 2022-09-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2019-05-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-04-22 | Eingeleitet | Ascendiant Capital Markets | Buy |
Alle ansehen
Outlook Therapeutics Inc Aktie (OTLK) Neueste Nachrichten
Outlook Therapeutics closes $5 million stock offering By Investing.com - Investing.com Australia
Published on: 2026-03-26 16:05:05 - baoquankhu1.vn
Outlook Therapeutics Announces $500,000 Public Offering of Common Stock and Warrants - Minichart
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants - TipRanks
Outlook Therapeutics closes 5.0 million dollar public offering to boost capital - Traders Union
Outlook Therapeutics commences $5.0M best-efforts offering of common stock with 1-for-1 warrants - TradingView
[8-K] Outlook Therapeutics, Inc. Reports Mat... - Stock Titan
Outlook Therapeutics closes $5 million stock offering - Investing.com
Outlook Therapeutics sells 20M shares, closes $5M financing - Stock Titan
Outlook Therapeutics (OTLK) launches 20M-share offering with detachable warrants - Stock Titan
Outlook Therapeutics prices $5M stock offering at $0.25 per share - Investing.com Australia
Outlook Therapeutics stock prices $5M offering at $0.25 per share amid Nasdaq plunge and biotech fun - AD HOC NEWS
Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced - marketscreener.com
Why is OTLK stock falling today? - MSN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
20M new shares at 25 cents: Outlook prices $5M fundraise - Stock Titan
Why Is OTLK Stock Falling Today? - Stocktwits
Biggest stock movers Tuesday: CLB, OTLK, and more (NASDAQ:NTGR) - Seeking Alpha
Outlook Therapeutics launches public stock offering By Investing.com - Investing.com Canada
Outlook Therapeutics announces proposed public offering sending shares into focus - Traders Union
Outlook Therapeutics (OTLK) Launches Public Offering, Shares Sli - GuruFocus
Outlook Therapeutics Announces Proposed Public Offering - The Manila Times
Outlook Therapeutics launches public stock offering - Investing.com
Outlook Therapeutics announces proposed public offering - marketscreener.com
Eye-disease drug developer seeks cash in stock-and-warrant sale - Stock Titan
Outlook Therapeutics (OTLK) offers common stock, pre-funded warrants and common warrants - Stock Titan
OTLK Stock Price, Quote & Chart | OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) - ChartMill
Whale Trades: Is Outlook Therapeutics Inc a top pick in the sector2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
Outlook Therapeutics secures $18.4M note, extends debt maturity By Investing.com - Investing.com India
Outlook Therapeutics Faces Substantial Doubt as a Going Concern Amid Funding Shortfall and Ongoing FDA Setbacks for ONS-5010/LYTENAVA 1234567 - Minichart
Outlook Therapeutics, Inc. announced that it has received $18.36 million in funding from Atlas Sciences, LLC - marketscreener.com
Outlook Therapeutics (OTLK) Restructures Debt with New Financing Moves - GuruFocus
Outlook Therapeutics Refinances Debt, Extends Note Maturities - TipRanks
Outlook Therapeutics Secures $17 Million Atlas Note to Refinance Avondale Debt - TradingView
Outlook Therapeutics (OTLK) refinances debt with $18.36M note amid going concern risks - Stock Titan
Outlook Therapeutics announces new $18.4 million non-convertible note financing and amendment to existing convertible note - marketscreener.com
Outlook Therapeutics secures $18.4M note, extends debt maturity - Investing.com
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note - Bitget
Outlook Therapeutics Amends Current Convertible Note With Avondale Capital To Extend Maturity Through Dec. 31; Signs $18.4M New NoteOutlook Therapeutics (NASDAQ:OTLK) - Benzinga
Outlook Therapeutics Announces New $18.4 Million - GlobeNewswire
Options Flow: Can Outlook Therapeutics Inc reach all time highs this year2026 Sentiment & Capital Efficient Trading Techniques - baoquankhu1.vn
Outlook Therapeutics Announces Board Resignation and Size Reduction - The Globe and Mail
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor - The Globe and Mail
Outlook Therapeutics' Dr. Julia Haller resigns from board; size reduced to nine - TradingView
Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026 - marketscreener.com
Outlook Therapeutics (NASDAQ: OTLK) trims board to nine directors - Stock Titan
Ascendiant Capital Lowers Price Target for Outlook Therapeutics (OTLK) | OTLK Stock News - GuruFocus
Shareholders at Outlook Therapeutics (NASDAQ: OTLK) approve board slate - Stock Titan
Outlook Therapeutics discusses FDA meeting on bevacizumab drug - Investing.com Nigeria
Published on: 2026-03-10 21:03:39 - baoquankhu1.vn
Key facts: Outlook Therapeutics Engages FDA on ONS-5010 Approval Pathways - TradingView
Finanzdaten der Outlook Therapeutics Inc-Aktie (OTLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):